Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eli Lilly (LLY) beats profit forecast amid soaring weight-loss drug demand
February 6, 2024 6:58 AM EST(Updated - February 6, 2024 8:26 AM EST)
Investing.com -- Eli Lilly (NYSE: LLY) has reported fourth-quarter revenue that topped estimates thanks in large part to soaring demand for its weekly diabetes injection.
The U.S. drugmaker's treatment -- branded as Mounjaro -- is in a race with a rival version from Denmark's Novo Nordisk to... More
